The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05010772
Recruitment Status : Recruiting
First Posted : August 18, 2021
Last Update Posted : June 6, 2024
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking a protein called Bcl-2 needed for cell growth. Gilteritinib, enasidenib, and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine alone or together with venetoclax, gilteritinib, enasidenib, or ivosidenib may help to control the disease.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Decitabine and Cedazuridine Drug: Enasidenib Drug: Gilteritinib Drug: Ivosidenib Drug: Venetoclax Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

I. To assess safety of patients with acute myeloid leukemia (AML) treated with decitabine and cedazuridine (oral decitabine)-based combinations as maintenance therapy after achieving remission.

SECONDARY OBJECTIVES:

I. To assess relapse-frees survival (RFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.

II. To assess overall survival (OS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.

III. To assess event-free survival (EFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.

IV. To assess the duration of remission (CRd) of patients with AML treated oral decitabine-based combinations as maintenance therapy.

V. To assess the effects of oral decitabine-based combinations on dynamics of minimal residual disease and their relationship to outcomes.

EXPLORATORY OBJECTIVE:

I. To evaluate RFS in (1) intensive induction cohort and (2) lower intensity induction cohort.

OUTLINE: Patients are assigned to 1 of 5 arms.

ARM A: Patients receive decitabine and cedazuridine orally (PO) once daily (QD) on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

ARM C: Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

ARM D: Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

ARM E: Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6-12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
Actual Study Start Date : October 25, 2021
Estimated Primary Completion Date : December 31, 2026
Estimated Study Completion Date : December 31, 2026


Arm Intervention/treatment
Experimental: Arm A (decitabine and cedazuridine)
Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Decitabine and Cedazuridine
Given PO
Other Names:
  • ASTX727
  • C-DEC
  • CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Tablet
  • DEC-C
  • Inqovi

Experimental: Arm B (decitabine and cedazuridine, venetoclax)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Decitabine and Cedazuridine
Given PO
Other Names:
  • ASTX727
  • C-DEC
  • CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Tablet
  • DEC-C
  • Inqovi

Drug: Venetoclax
Given PO
Other Names:
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclexta
  • Venclyxto

Experimental: Arm C (decitabine and cedazuridine, gilteritinib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Decitabine and Cedazuridine
Given PO
Other Names:
  • ASTX727
  • C-DEC
  • CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Tablet
  • DEC-C
  • Inqovi

Drug: Gilteritinib
Given PO
Other Names:
  • ASP-2215
  • ASP2215

Experimental: Arm D (decitabine and cedazuridine, enasidenib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Decitabine and Cedazuridine
Given PO
Other Names:
  • ASTX727
  • C-DEC
  • CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Tablet
  • DEC-C
  • Inqovi

Drug: Enasidenib
Given PO
Other Names:
  • AG-221
  • CC-90007 Free Base

Experimental: Arm E (decitabine and cedazuridine, ivosidenib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Decitabine and Cedazuridine
Given PO
Other Names:
  • ASTX727
  • C-DEC
  • CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Combination Agent ASTX727
  • Cedazuridine/Decitabine Tablet
  • DEC-C
  • Inqovi

Drug: Ivosidenib
Given PO
Other Names:
  • AG-120
  • Tibsovo




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Up to 5 years ]
    Safety analyses in general will be descriptive and will be presented in tabular format with the appropriate summary statistics. Adverse events will be tabulated using frequency and percentage by severity and by relations to the treatments for each arm.


Secondary Outcome Measures :
  1. Relapse-free survival (RFS) [ Time Frame: From complete remission or complete remission with incomplete count recovery until date of first objective documentation of relapse or death, assessed up to 5 years ]
    The Kaplan-Meier method will be used to estimate RFS.

  2. Overall survival (OS) [ Time Frame: From date of treatment start until date of death due to any cause, assessed up to 5 years ]
    The Kaplan-Meier method will be used to estimate OS.

  3. Event-free survival (EFS) [ Time Frame: From treatment start until date of first documented event., assessed up to 5 years ]
    Event will be defined as: confirmed relapse, withdrawal from study due to adverse event, or death due to any cause. The Kaplan-Meier method will be used to estimate EFS.

  4. Duration of remission [ Time Frame: Up to 5 years ]
    The Kaplan-Meier method will be used to duration of remission.

  5. Minimal residual disease [ Time Frame: Up to 5 years ]
    The log rank test and Cox proportional hazards model will be used to evaluate the association between the time to event outcomes and status of residual disease.


Other Outcome Measures:
  1. RFS (Intensive induction cohort) [ Time Frame: Up to 5 years ]
    Kaplan-Meier method will be used to estimate RFS for intensive induction cohort.

  2. RFS (Lower intensity induction cohort) [ Time Frame: Up to 5 years ]
    Kaplan-Meier method will be used to estimate RFS for lower intensity induction cohort.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged >= 18 years AML who have achieved their FIRST complete response (CR) or complete response with incomplete bone marrow recovery (CRi) and are not immediately candidates for allogeneic stem cell transplant
  • Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be designated as COHORT 1 (intensive induction cohort)
  • Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be designated as COHORT 2 (lower intensity induction cohort)
  • For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement
  • Eastern Cooperative Oncology Group (ECOG) performance status of < or = 3
  • Serum total bilirubin < or = to 1.5 x the upper limit of normal (ULN)
  • Serum creatinine < or = to 2.5 x ULN
  • Absolute neutrophil count (ANC) > 0.5 x k/uL
  • Platelet count > or = 50 x k/uL
  • For females of childbearing age, they may participate if they:

    • Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
    • Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment
  • For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment
  • Ability to understand and sign informed consent

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
  • Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor
  • Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with active CNS (central nervous system) disease
  • Patients with documented hypersensitivity to any components of the study program
  • Females who are pregnant or lactating or intending to become pregnant during the study
  • Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment
  • Patient should be removed from current trial if they wish to participate and get treatment on another trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05010772


Contacts
Layout table for location contacts
Contact: Tapan M. Kadia, MD 713-792-7305 tkadia@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Tapan M. Kadia    713-792-7305    tkadia@mdanderson.org   
Principal Investigator: Tapan M. Kadia         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Tapan M Kadia, MD M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT05010772    
Other Study ID Numbers: 2021-0237
NCI-2021-08496 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2021-0237 ( Other Identifier: M D Anderson Cancer Center )
First Posted: August 18, 2021    Key Record Dates
Last Update Posted: June 6, 2024
Last Verified: June 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Hematologic Diseases
Venetoclax
Decitabine
Decitabine and cedazuridine drug combination
Ivosidenib
Gilteritinib
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors